Latest News
Stay up to date with the latest developments in myasthenia gravis research, advocacy, and community support. Explore news, events, and policy updates to stay informed and get involved.
Browse our categories to explore stories relevant to you, and stay connected with the MG community.
- All
- About MAA News Items
- Annual Conference News Items
- Art With Heart News Items
- Get Involved News Items
- Health Professionals News Items
- Living with MG News Items
- MG Awareness Month News Items
- Patient Tool Kit
- Policy Makers News Items
- Understanding MG News Items
Market research on Generalized Myasthenia Gravis (gMG)
The MAA respectfully requests patient support in further telling the story of their experiences with all forms of Myasthenia. Please note, we are very pleased that this survey can be completed via a hardcopy option. Please call Libby on 0407 110 204 to arrange this. Late last year Alexion asked several people living with MG…
Final Reminder – Partnering With Canada
To Australians with Myasthenia, the following is a message from Dr Carolina Barnette-Tapia MD, PhD of Canada. The MAA thank Australians for their interest in supporting this project. Responses will be welcomed until early September 2024. Information about the outcomes resulting from this research has been requested. Disclosure information is provided after logging in. “We…
Research Report
The Myasthenia Alliance Australia (MAA) supports and promotes research that is specific to the experience of Myasthenia Gravis (MG) patients in Australia. But we would not be able to do this without the essential and valuable contribution of Australians with MG. One current project is VALUE-Ig, which aims to generate evidence to inform the optimal…
UPDATED – Participate in a focus group to help design research for MG patients
Participate in a focus group to help design research for MG patients
Industry Engagement Opportunity for AChR+ MG Patients – The MAA appreciates your interest in this market research if you feel you can help.
Industry Engagement Opportunity AChR+ MG Patients